CAS 100986-85-4 Levofloxacin Powde API Pwoder Antibacterial

• Powder: Yes
• Customized: Non-Customized
• Certification: GMP, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >98%
• Model NO.: HNB-Levofloxacin
• CAS: 304-55-2
• Molecular Weight: 182.218
• Molecular Formula: C4h6o4s2
• Einecs: 206-155-2
• Transport Package: Aluminum Foil Bag/Drum
• Specification: 98%
• Trademark: HNB BIOTECH
• Origin: China-Xian

Product Description

Cas 100986-85-4 Levofloxacin powde API pwoder antibacterial

Production Introduction:
 

 

Levofloxacin is a synthetic fluoroquinolone antibiotic that inhibits the superhelical activity of bacterial DNA rotase, which prevents DNA replication.

Application:

Use 1
Mainly used in the manufacture of various kinds of levofloxacin capsules, tablets and other antibacterial preparations
Use 2
It is a fully synthetic antibiotic for the treatment of respiratory tract, urinary tract and skin tissue infections
Use 3
Levofloxacin has excellent in vitro activity, less toxic side effects than ofloxacin, greater safety and good pharmacokinetic properties. It can be widely used in respiratory tract infection, gynecological disease infection, skin and soft tissue infection, surgical infection, biliary tract infection, sexually transmitted diseases, ear, nose and mouth infection and other bacterial infections, which is an oral or gastrointestinal application of broad spectrum fluoroquinolone antibacterial drug.
Use 4
It is a fully synthetic antibiotic for the treatment of various bacterial infections. This product has a broad spectrum antibacterial action, antibacterial action is strong, and has strong antibacterial activity against most enterobacteriaceae bacteria, such as Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella and Haemophilus influenzae, Legionella pneumophila, Neisseria gonorrhoea and other gram-negative bacteria. It also has antibacterial effect on Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes and other gram-positive bacteria, mycoplasma pneumoniae and chlamydia pneumoniae, but it has poor effect on anaerobic bacteria and enterococcus. This product is the levofloxacin, and its antibacterial activity in vitro is about twice that of ofloxacin. The mechanism of action is to prevent the synthesis and replication of bacterial DNA by inhibiting the activity of bacterial DNA rotation enzyme, which leads to bacterial death.